Celgosivir has passed safety studies in humans (Sels et al. 1999; Rathore et al. 2011). N-butyl-deoxynojirimycin (Miglustat) has been approved for clinical use since 2002 for Gaucher’s disease (Cox et al. 2000; Lachmann 2003), after tests in 2000 to show its activity was to decrease substrate biosynthesis. This safety data suggests that both should be investigated repurposed off-label for COVID19 infectivity, since safety, PK and dosage has already been established. Also, long-term, 24-month studies of Miglustat have established safety and efficacy (Pastores et al. 2005), where COVID19 treatment may require very brief application. Chang et al. (2013b) and Pérez-García et al. (2017) reviewed and recommended the use of ER glycosylation inhibitors as potential targets for viral therapeutics. Main side effects were GI, manageable by diet and anti-propulsives. Duvoglustat, (1-deoxymannojirimycin) (Fuhrmann et al. 1984) amphomycin and related compounds should also be tested. Considering the seriousness of this pandemic, researchers with access to these and other glycosylation inhibitors should collaborate with virology labs that can test the infectivity cycle of SARS COV2.